FGI-106tetrahydrochloride是一种有效的广谱抑制剂，对多种病毒具有抑制活性。FGI-106tetrahydrochloride具有抗埃博拉病毒(EBOV)，裂谷病毒(RiftValleyvirus)和登革热病毒(DengueFevervirus)的活性，其EC50分别为100nM，800nM和400-900nM。FGI-106tetrahydrochloride还分别以EC50值为200nM和150nM抑制非失血性发热病毒HCV和HIV-1。
FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively[1].
Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM[1].In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses[1].
FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner[1]. Animal Model: Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus)[1]
[1]. Aman MJ, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009 Sep;83(3):245-51.
动态评分
0.0